Last updated on December 2019

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection


Brief description of study

The main purpose of study is to compatibility the pharmacokinetic (PK) of Process D relative to Process C.

Detailed Study Description

The study is intended to compare the pharmacokinetic of Process D nivolumab to Process C nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV melanoma.

Clinical Study Identifier: NCT03980314

Find a site near you

Start Over

Local Institution

Badalona-barcelona, Spain
9.57miles
  Connect »